governance and ethics
As a private UK company infirst Healthcare Ltd is not listed on any public stock exchange. Its shareholders comprise Biocopea Ltd (an entity within the SEEK Group) and five investment funds, four of which are represented by Invesco Perpetual Asset Management (one of the UK’s largest and most successful independent investment funds).
The business is managed by a Leadership team with many decades of industry experience. This team strives to manage the business through the development and application of consistent and cohesive policies, guidelines, processes and decision making authorities. The Leadership team is accountable to the Board of Directors, which is chaired by Dr Lynn Drummond, formerly a managing director at N.M. Rothschild investment bank, who also has considerable experience in the healthcare industry.
Dr. Lynn Drummond has a strong track record within the life sciences sector, bringing over twenty five years of management and advisory experience. Lynn spent 16 years at Rothschild in London most recently as a Managing Director within the investment banking division, with a particular focus on transactions within the healthcare sector. Prior to this she worked in the Cabinet Office in London as Private Secretary to the Chief Scientific Advisor. She spent the early part of her career as a research scientist, including a year in Tokyo, Japan as a post-doctoral research fellow.
Lynn is currently Non-Executive Chairman of infirst Healthcare, Non-Executive Chairman of Venture Life plc and a Non-Executive Director of RPC Group plc and Shield Holdings AG.
Dr. Drummond holds a Bachelor of Science Degree in Chemistry from the University of Glasgow and a PhD in Biochemistry from the University of London. She is a Fellow of the Royal Society of Edinburgh and a Fellow of the Royal Society of Chemistry.
Manfred is Chief Executive Officer and a member of the Board of infirst Healthcare. Manfred was latterly President of GlaxoSmithKline's Consumer Health business across Europe, having previously led the North-American and German businesses. He enjoyed 25 highly successful years at GSK and its legacies and has also given long service to industry trade association boards in both the US and Europe. Manfred studied Business and Economics at The University of Cologne.
Andrew joined infirst Healthcare as Chief Financial Officer and a member of the Board in January 2013. He is a chartered accountant with more than 20 years' experience in the pharmaceutical and consumer healthcare industries. Andrew is a Physics graduate of Imperial College London and worked at GlaxoSmithKline for over 16 years, in a series of senior financial roles. Andrew started his career at Price Waterhouse Coopers in London.
Gregory is Non-Executive Director of infirst Healthcare and Chief Executive Officer of SEEK (formerly known as PepTcell) which he founded in 2004, after a distinguished 20 year career in investment banking at Deutsche Bank and UBS. He has worked on numerous mergers, acquisitions and structured finance deals in the healthcare industry, including mergers by GlaxoSmithKline, Aventis and Pfizer. Gregory has also worked in project finance for major pharmaceutical company clients such as Roche, Merck and Novartis. He has a wealth of experience in advising and working with medical research companies across Australasia, USA and Europe.
Gregory is a qualified Chartered Accountant and has spent many years researching scientific medical issues, specifically related to the immune system. He has had several scientific papers published, many specialising in the area of research into peptides and is listed as an inventor in numerous patents for cancer, HIV, mosquito-borne diseases and influenza.
Kim is a Non-Executive Director of infirst Healthcare. He began his career as a trader at Goldman Sachs in 1987, moving to Nomura, Credit Suisse and Mizuho, leading teams conducting principal investment activities in which the firms' capital was invested directly for their own account. His major transactions include the acquisitions of Inntrepreneur Pub chain, Angel Trains, AT&T Capital and Stenvalvet AB. Kim has extensive experience in structured finance, leveraged finance and credit derivatives trading. He is a graduate of Yale University and sits on the boards of other early stage ventures including SEEK, Curemark LLP, Pharmajet Inc, Spatial View Inc., and Ignite Gaming Technologies. In 2010, Kim co-founded the Rush Foundation, which aims to fund disruptive ideas against HIV in sub-Saharan Africa.
wait until something is "seriously wrong" before seeing their GP